Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas.

作者: Martin H. Schuler , Zanete Zvirbule , Florian Lordick , Anna Krilova , Ulrike Helbig

DOI: 10.1200/JCO.2013.31.15_SUPPL.4080

关键词:

摘要: 4080 Background: IMAB362 is a monoclonal antibody targeting isoform 2 of the tight junction component claudin 18 (CLDN18. 2), a tumor-selective antigen frequently expressed in several types of epithelial adenocarcinomas. Preclinically, IMAB362 exerts its antitumor activity by ADCC, CDC, induction of apoptosis and inhibition of cell proliferation. Methods: Patients with treatment-refractory, metastatic gastroesophageal adenocarcinomas with CLDN18. 2-positive tumors as determined by immunohistochemistry were enrolled in two …

参考文章(0)